Dashboard
Weak Long Term Fundamental Strength with a -188.85% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.74
- The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
Stock is technically in a Mildly Bearish range
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Biotechnology
INR 29 Cr (Micro Cap)
NA (Loss Making)
27
0.00%
-0.22
-0.04%
0.25
Total Returns (Price + Dividend) 
Latest dividend: 0.3800 per share ex-dividend date: Sep-20-2012
Risk Adjusted Returns v/s 
Returns Beta
News

Medi Caps Ltd Locks at Lower Circuit With 3.9% Loss — Sellers Queue, No Buyers in Sight
At Rs 21.66, sellers were still queuing — but there were no buyers willing to take the other side. Medi Caps Ltd locked at its lower circuit of 5% on 18 Nov 2026, with unfilled sell orders and a frozen price that capped losses at 3.91% for the session.
Read More
Medi Caps Ltd Locks at Lower Circuit With 4.96% Loss — Sellers Queue, No Buyers in Sight
At Rs 22.79, sellers were still queuing — but there were no buyers willing to take the other side. Medi Caps Ltd locked at its lower circuit of 4.96% on 17 Nov 2026, with unfilled sell orders and a frozen price.
Read More
Medi Caps Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight
At Rs 22.42, sellers were still queuing — but there were no buyers willing to take the other side. Medi Caps Ltd locked at its lower circuit of 5% on 16 Nov 2026, with unfilled sell orders and a frozen price.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSEExtract of unaudited standalone and consolidate financial results of the company for the quarter/half year ended 30.09.2026 published in free press English edition and choutha sansar Hindi edition dated 06.11.2026. copy of same is attached.
Submission Of Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended 30.09.2026
04-Nov-2026 | Source : BSESubmission of unaudited standalone & Consolidated Financial Results for the quarter & Half year ended 30.09.2026
Board Meeting Outcome for Submission Of Unaudited Standalone & Consolidated Financial Result For The Quarter And Half Year Ended 30.09.2026
04-Nov-2026 | Source : BSESubmission of Unaudited Standalone & Consolidated financial Result for the quarter and half year ended 30.09.2026
Corporate Actions 
No Upcoming Board Meetings
Medi Caps Ltd has declared 15% dividend, ex-date: 20 Sep 12
No Splits history available
Medi Caps Ltd has announced 3:1 bonus issue, ex-date: 19 Mar 13
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Alok K Garg (26.26%)
Sangeetha S (5.55%)
43.88%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 107.17% vs -19.13% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 95.96% vs -173.36% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -67.56% vs 16.85% in Sep 2024
Growth in half year ended Sep 2025 is -2,112.50% vs 76.00% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -51.38% vs -4.93% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -165.50% vs -97.41% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -51.12% vs -6.84% in Mar 2025
YoY Growth in year ended Mar 2026 is -433.33% vs 74.55% in Mar 2025